Recipharm Reduces Risk and Improves Compliance with Infor
News Jul 09, 2015
Recipharm has deployed the industry cloud company Infor M3. Infor M3’s ERP (Enterprise Resource planning) application will help reduce risk by enabling standard processes across all Recipharm manufacturing facilities in Sweden.
Following a period of organic and acquisitive growth, Recipharm sought to streamline its ERP system as part of a strategy to reduce the risks presented by a fragmented suite of legacy applications. Following a lengthy selection process, Infor M3 was chosen as it needed fewer customizations, was quicker to implement and offered a lower total cost of ownership.
The application was implemented by Infor partner Merit Globe. The project included integration with third party systems as well as a migration from IBM AS/400 to Microsoft SQL.
“Infor M3 is inherently less complex than comparable systems, and we were impressed by Infor’s substantial investment in the application,” said Mikael Porat, director of supply chain, Recipharm. “We can see that new features are being developed and industry-specific functionality added, removing the need for customization. This is critical for us as we instigate business process improvement projects. Looking ahead we are assessing options outside of the ERP such as electronic signature (ES), as this is of major importance for compliance within the pharmaceutical industry.”
“Success in the pharmaceutical industry depends on managing two contrasting factors, continual product innovation and complete compliance with regulations,” said Mark Humphlett, director, Industry and Solution Strategy, Infor. “From an operational perspective this means an agile ERP and standardized processes are critical. Customizations must be kept to a minimum and integration must be lightweight and flexible to support growth. Through implementing Infor M3 throughout its operations, Recipharm can have confidence that both of these driving forces are being supported.”
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE